Perfusion Medical has concluded the year on a high note, having successfully raised over $1.85 million in a seed round to fund the development of a game-changing drug for the treatment of hemorrhagic shock and other ischemic conditions.

Perfusion Medical is an emerging biopharmaceutical company developing lifesaving, acute cardiovascular therapies to transform critical care medicine, with a focus on shock and ischemic conditions. Funds raised will be used to complete the filing of its Investigational New Drug (IND) application, as well as to hire key technical personnel and advance the research and development of new products.